Biosolutions
Sales for 2024 at Biosolutions were up 11.2 percent to €374.9 million (2023: €337.2 million). The positive trend was bolstered primarily by growth in its biopharmaceutical business. From a regional perspective, sales increased considerably in Asia and Europe, whereas they remained stable at the prior-year level in the Americas.
EBITDA of €35.1 million was markedly higher than the year before (2023: €6.5 million). The EBITDA margin was 9.4 percent (2023: 1.9 percent).
Capital spending fell compared to the previous year, down from €155.5 million in 2023 to €49.3 million in 2024. The division’s investment focus was on its new mRNA Competence Center in Halle, which was opened in June. The number of employees as of December 31, 2024, totaled 1,189 (December 31, 2023: 1,191).
€ million |
|
2024 |
|
2023 |
|
2022 |
|
2021 |
|
2020 |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Total sales |
|
374.9 |
|
337.2 |
|
331.1 |
|
296.4 |
|
246.1 |
EBITDA |
|
35.1 |
|
6.5 |
|
16.7 |
|
38.6 |
|
38.1 |
EBITDA margin (%) |
|
9.4 |
|
1.9 |
|
5.0 |
|
13.0 |
|
15.5 |
EBIT |
|
-17.1 |
|
-20.1 |
|
-4.7 |
|
20.7 |
|
21.6 |
Capital expenditures |
|
49.3 |
|
155.5 |
|
102.6 |
|
33.5 |
|
19.9 |
R&D expenses |
|
9.6 |
|
5.5 |
|
4.8 |
|
5.6 |
|
5.7 |
Employees (number as of Dec. 31) |
|
1,189 |
|
1,191 |
|
835 |
|
751 |
|
764 |
